Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using B6 and Zinc to inhibit 5ar activity, similar to Fin and Dut. Minoxidil is mentioned as a supplementary treatment.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

Actifolic's RU58841 and Pyri products are perceived as ineffective, with users reporting no side effects or improvements, suggesting possible quality issues. Users recommend alternative sources and emphasize the importance of timing when using RU58841 with Minoxidil.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

A user is making a 2-Deoxy-D-ribose solution and asks if it can be put into an oil instead of a gel, considering adding hydrocortisone and retinoic acid. They seek advice on the best carrier oil for hair growth.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

A user is treating hair loss with Dutasteride, Minoxidil, RU58841, Derminator 2, Vitamin D, Biotin, and Zinc. After 6 months, there's no significant visual improvement, but the user feels less insecure about Retrograde Alopecia.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

Managing estradiol levels while using finasteride. Treatments discussed include Minoxidil, finasteride, and RU58841.

A 17-year-old with AGA is considering Revitacare Haircare Mesotherapy, which includes hyaluronic acid, amino acids, zinc, and B vitamins, injected into the scalp. One reply dismisses it as ineffective.

A 24-year-old male with aggressive androgenetic alopecia is using 1mg finasteride daily and considering a treatment stack including 0.5mg dutasteride, 2.5mg oral minoxidil, ketoconazole shampoo, Alpecin caffeine shampoo, and RU58841. He seeks advice on the safety and effectiveness of these treatments and whether any adjustments are needed.

User considers trying Pyrilutamide for hair loss and itch relief. Another user shares positive experience with Pyrilutamide, no side effects.

Taking 2.5mg of dutasteride daily can cause feelings of low energy, ambition, and motivation, likely due to hormonal imbalances. Many users suggest lowering the dose to 0.5mg to alleviate these side effects.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The user is concerned about high DHT levels despite using finasteride and dutasteride for hair loss, suggesting these treatments may not be effective. They plan to consult an endocrinologist and consider other antiandrogens, acknowledging potential side effects.

RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.

Stress can increase androgen sensitivity, potentially worsening hair loss. Treatments discussed include Minoxidil, finasteride, and RU58841.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

The conversation discusses a live stream presentation on Pelage PP405 for hair regrowth, with skepticism about its effectiveness compared to minoxidil. Some users express doubt and suggest sticking to proven treatments like minoxidil, finasteride, and RU58841.

The user tried Minoxidil without success, and Finasteride worked but caused sexual side effects even at a very low dose. They are seeking alternative treatments for hair loss as they cannot tolerate anti-androgens and are also in therapy for mental health.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

A user discusses switching from RU58841 to Pyrilutamide due to side effects like fatigue, brain fog, and elevated heart rate. They have used dutasteride, finasteride, and minoxidil, and are seeking safer alternatives.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

The conversation discusses Procapil, a treatment for hair loss containing Apigenin and Oleanolic acid. Users are sharing their experiences and asking if anyone has tried it.